8000 Marina Boulevard
About Aimmune Therapeutics
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients.
136 articles with Aimmune Therapeutics
Aimmune Therapeutics, Inc. announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. E.T. in New York City.
Aimmune’s peanut allergy treatment is one-step closer to approval following strong support from the Allergenic Products Advisory Committee, which overwhelmingly recommended approval of Palforzia, the proposed trade name of the investigational oral treatment, AR101.
FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy
Aimmune Therapeutics, Inc. announced that the Allergenic Products Advisory Committee convened by the U.S. Food and Drug Administration voted to support the use of AR101 in children and teens with peanut allergy.
Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy
Aimmune Therapeutics, Inc. announced that NASDAQ has halted trading of the company’s common stock.
Aimmune Therapeutics, Inc. announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in September
Aimmune Therapeutics, Inc. announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg allergy.
Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights
Aimmune Therapeutics, Inc. announced financial results for the quarter and six months ended June 30, 2019.
Jayson Dallas, M.D., will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, at 3:05 p.m. E.T. in New York City.
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, announced that it will host a conference call on Thursday, August 8, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2019, and recent operational highlights.
Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy
Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community
7/3/2019Companies from across the globe provide information on agreements and pipeline updates.
Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy
Aimmune Therapeutics, Inc. announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for AR101, an investigational biologic oral immunotherapy to reduce the frequency and severity of allergic reactions following exposure to peanuts in children and adolescents ages 4 to 17.
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 2:30 p.m. E.T. in New York
Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting
Company to Share Updated Clinical Data on AR101 and Provide Perspective on Its Value to Society
Aimmune Therapeutics, Inc. announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40th Annual Healthcare Conference on Wednesday, June 12, 2019 at 9:20 a.m. P.D.T.
New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
Aimmune Therapeutics, Inc. announced results from ARC004, an open-label, rollover study of the landmark Phase 3 PALISADE trial, which showed that extending daily therapy with AR101 by an additional 28 weeks led to improved tolerability with lower numbers of adverse events compared to the PALISADE therapeutic dosing period, an increase in the amount of peanut that could be safely ingested, and continued immunomodulation to peanut protein in most patients.
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, announced new data from two studies that assessed the psychosocial burden of living with peanut allergy.
The add-on data showed that longer treatment with AR101 provided higher tolerance levels to peanut protein.
Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
Aimmune Therapeutics, Inc. presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had met its primary endpoint, demonstrating the efficacy and safety of AR101 in peanut-allergic children and adolescents after six months of dose escalation and a three-month therapeutic dosing phase.
Full Results from Phase 3 ARTEMIS Study Will Be Featured